Dova Pharmaceuticals (NASDAQ:DOVA) Given New $15.00 Price Target at JPMorgan Chase & Co.

Dova Pharmaceuticals (NASDAQ:DOVA) had its target price increased by JPMorgan Chase & Co. from $13.00 to $15.00 in a research report released on Friday, BenzingaRatingsTable reports. The firm currently has an underweight rating on the stock.

A number of other equities research analysts have also recently commented on the company. Wedbush set a $190.00 price target on Home Depot and gave the company a hold rating in a research note on Wednesday, May 22nd. Zacks Investment Research cut ExlService from a hold rating to a sell rating in a research note on Wednesday, July 10th. Evercore ISI upgraded Dova Pharmaceuticals from an in-line rating to an outperform rating and set a $15.00 price target for the company in a research note on Monday, July 1st. HC Wainwright increased their price target on Dova Pharmaceuticals from $18.00 to $39.00 and gave the company a buy rating in a research note on Thursday, June 27th. Finally, BidaskClub upgraded Zillow Group from a buy rating to a strong-buy rating in a research note on Tuesday, July 2nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $27.13.

Dova Pharmaceuticals stock opened at $16.06 on Friday. The company has a 50-day simple moving average of $11.75. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.46 and a quick ratio of 4.27. Dova Pharmaceuticals has a one year low of $5.62 and a one year high of $26.49.

Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.10. Dova Pharmaceuticals had a negative return on equity of 87.20% and a negative net margin of 521.67%. The company had revenue of $4.00 million during the quarter, compared to analysts’ expectations of $3.46 million. As a group, equities analysts predict that Dova Pharmaceuticals will post -2.1 earnings per share for the current year.

In other news, CEO David Zaccardelli sold 10,450 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $15.94, for a total value of $166,573.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jason Hoitt sold 2,387 shares of the firm’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $13.81, for a total value of $32,964.47. The disclosure for this sale can be found here. Over the last 90 days, insiders bought 582,854 shares of company stock valued at $8,243,825 and sold 18,838 shares valued at $284,611. Company insiders own 60.30% of the company’s stock.

Large investors have recently made changes to their positions in the company. Spark Investment Management LLC raised its stake in shares of Dova Pharmaceuticals by 31.8% in the first quarter. Spark Investment Management LLC now owns 80,500 shares of the company’s stock worth $715,000 after purchasing an additional 19,400 shares during the last quarter. Sanders Morris Harris LLC acquired a new stake in Dova Pharmaceuticals during the first quarter worth about $2,507,000. PNC Financial Services Group Inc. grew its holdings in Dova Pharmaceuticals by 14,705.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 5,034 shares of the company’s stock worth $38,000 after acquiring an additional 5,000 shares during the period. Sphera Funds Management LTD. grew its holdings in Dova Pharmaceuticals by 54.2% during the fourth quarter. Sphera Funds Management LTD. now owns 185,000 shares of the company’s stock worth $1,402,000 after acquiring an additional 65,000 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Dova Pharmaceuticals by 8.1% during the fourth quarter. Geode Capital Management LLC now owns 156,232 shares of the company’s stock worth $1,184,000 after acquiring an additional 11,732 shares during the period. Hedge funds and other institutional investors own 30.18% of the company’s stock.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

See Also: Google Finance Portfolio

Analyst Recommendations for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.